PSYLOSYS
Voice Biomarkers as a Tool for Investigating Neuropsychological Effects of Microdosing Psychedelics
Overview
This study will explore the relationship between speech, mood, creativity and cognitive functions in psychedelic microdosers. Specifically it will investigate whether microdosing psilocybin or LSD results in unique speech biomarker patterns during and after use.
Given the antidepressant properties of psychedelics and their effects on mood, creativity and cognitive flexibility, these elements will be evaluated at baseline, during, and after psychedelic microdosing. This will be the first study to analyze speech dynamics in relation to psychedelic states and their impact on mood, creativity, insight, and cognition.
Participants will complete neuropsychological tests, verbal tasks, and surveys via a web app, ensuring accessibility and diversity. This large-scale, anonymous study aims to measure the real-world effects of psychedelic microdosing on mood and cognition, potentially uncovering new mechanisms of action and providing preliminary evidence for further research.
Recent findings suggest that microdosing can affect speech patterns. This study aims to validate these results in a larger sample and correlate speech changes with psychotherapeutic benefits. Speech biomarkers, derived from speech patterns, can offer objective insights into mental and emotional states, enhancing the understanding of benefits of microdosing for mental well-being and monitoring the effectiveness of microdosing schedules.
Data will be analyzed using advanced voice analytics and machine learning, with the goal of identifying voice biomarkers which can predict therapeutic effects and effective microdosing regimes.
Study Objectives:
- Examine the impact of microdosing psychedelics on mood, cognition, and speech.
- Identify speech biomarkers associated with microdosing.
- Correlate changes in speech with mood, cognition, and creativity.
- Assess the feasibility of using voice analytics to monitor therapeutic responses in microdosers.
Benefits:
Participants will contribute to groundbreaking research that could enhance our understanding of the therapeutic effects of psychedelics. This study has the potential to:
Identify new biomarkers for monitoring mood and cognitive changes.
Improve the precision and personalization of psychedelic therapies.
Provide insights into optimal microdosing regimens for therapeutic benefits.
Advance mental health treatment strategies by integrating speech analytics with traditional psychological assessments.
Inclusion Criteria:
- 18 years of age or older
- Full legal and mental capacity
- Access to a smartphone or computer with internet to fill in the study measures and complete regular neuropsych tests and audio recordings
- Active microdoser of a psychedelic ie psilocybin or LSD
Exclusion Criteria:
- Family history or clinical diagnosis of bipolar, schizophrenia or cognitive impairment
- Currently taking any anti-psychotic medication or antidepressants
- Lack of proficiency in English
- Full dose psychedelic use in the previous month
